MX2022004516A - Metodo y composicion para aumentar la sintesis de proteinas musculares. - Google Patents
Metodo y composicion para aumentar la sintesis de proteinas musculares.Info
- Publication number
- MX2022004516A MX2022004516A MX2022004516A MX2022004516A MX2022004516A MX 2022004516 A MX2022004516 A MX 2022004516A MX 2022004516 A MX2022004516 A MX 2022004516A MX 2022004516 A MX2022004516 A MX 2022004516A MX 2022004516 A MX2022004516 A MX 2022004516A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- protein synthesis
- increasing muscle
- muscle protein
- carnitine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000008934 Muscle Proteins Human genes 0.000 title abstract 2
- 108010074084 Muscle Proteins Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000001243 protein synthesis Methods 0.000 title abstract 2
- 230000014616 translation Effects 0.000 title abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 3
- 229960003624 creatine Drugs 0.000 abstract 3
- 239000006046 creatine Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- -1 nitrogenous organic acid Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe un método y composición para aumentar la síntesis de proteínas musculares en mamíferos. En una modalidad, a los mamíferos se les administra una composición de construcción de proteínas que comprende un componente de aminoácidos que incluye L-carnitina y un ácido orgánico nitrogenado que incluye creatina. En una modalidad particular, la creatina está en una solución con L-carnitina. La relación de L-carnitina con respecto a creatina puede ser de alrededor de 10:1 a alrededor de 1:1. La composición de construcción de proteínas se puede administrar en una cápsula entérica monolítica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915709P | 2019-10-16 | 2019-10-16 | |
| US202063021755P | 2020-05-08 | 2020-05-08 | |
| PCT/US2020/056025 WO2021076920A1 (en) | 2019-10-16 | 2020-10-16 | Method and composition for increasing muscle protein synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004516A true MX2022004516A (es) | 2022-07-12 |
Family
ID=75538340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004516A MX2022004516A (es) | 2019-10-16 | 2020-10-16 | Metodo y composicion para aumentar la sintesis de proteinas musculares. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220370392A1 (es) |
| EP (1) | EP4027990A4 (es) |
| CA (1) | CA3153332A1 (es) |
| MX (1) | MX2022004516A (es) |
| WO (1) | WO2021076920A1 (es) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| FR2779962B1 (fr) | 1998-06-17 | 2002-12-06 | Karim Ioualalen | Composition cosmetique ou dermopharmaceutique sous forme de perles et procedes pour la preparation |
| US6784209B1 (en) * | 1999-10-18 | 2004-08-31 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
| US20010053791A1 (en) | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| DE10119946A1 (de) * | 2001-04-24 | 2003-04-30 | Joachim Steuer | Zugabe von CLA(konjugierte Linolsäure) und/oder Kreatin und/oder L-Carnitin zu einer an sich üblichen Brausetablette |
| BRPI0417348A (pt) | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo |
| WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
| JP2007513145A (ja) | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 医薬用多微粒子の製造方法 |
| FR2879930B1 (fr) | 2004-12-23 | 2007-08-31 | Oralance Pharma Sa | Nouveau systeme galenique pour le transport d'actif, procede de preparation et utilisation |
| US20070015686A1 (en) * | 2005-07-07 | 2007-01-18 | Heuer Marvin A | Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
| US8546369B2 (en) | 2008-05-30 | 2013-10-01 | Northern Innovations Holding Corp. | Salts of creatine imino sugar amides |
| US20100055178A1 (en) * | 2008-08-29 | 2010-03-04 | Adel Vilallobos | Enteric-coated creatine compositions and methods of use thereof |
| BR112012006651B1 (pt) * | 2009-09-24 | 2021-11-03 | Capsugel Belgium Nv | Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc |
| US10869843B2 (en) * | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
| US8828426B2 (en) * | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
| WO2013177458A1 (en) * | 2012-05-23 | 2013-11-28 | Chemi Nutra | Compositions for increasing strength, muscle mass, and lean body mass |
| ITTO20121098A1 (it) | 2012-12-18 | 2014-06-19 | Univ Degli Studi Genova | Procedimento per sintetizzare derivati della creatina |
| WO2015065848A1 (en) | 2013-11-04 | 2015-05-07 | Capsugel Belgium Nv | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
| EP3226845A1 (en) * | 2014-12-04 | 2017-10-11 | Capsugel Belgium NV | Lipid multiparticulate formulations |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| US20170348235A1 (en) * | 2015-09-16 | 2017-12-07 | Corr-Jensen, Inc. | Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates |
| BR112018012410B1 (pt) * | 2015-12-18 | 2022-12-20 | Lonza Consumer Health Inc | Composição para o aumento da síntese de proteína e/ou força funcional musculares em mamíferos |
| US20170360735A1 (en) * | 2016-06-21 | 2017-12-21 | Dreampak | Ingestible emulsion matrix for delivery of creatine |
| WO2018035027A1 (en) * | 2016-08-15 | 2018-02-22 | Corr-Jensen Inc. | TIME RELEASE OF CoQ10 |
-
2020
- 2020-10-16 US US17/765,156 patent/US20220370392A1/en active Pending
- 2020-10-16 CA CA3153332A patent/CA3153332A1/en active Pending
- 2020-10-16 MX MX2022004516A patent/MX2022004516A/es unknown
- 2020-10-16 WO PCT/US2020/056025 patent/WO2021076920A1/en unknown
- 2020-10-16 EP EP20876060.3A patent/EP4027990A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4027990A4 (en) | 2023-10-18 |
| US20220370392A1 (en) | 2022-11-24 |
| CA3153332A1 (en) | 2021-04-22 |
| WO2021076920A1 (en) | 2021-04-22 |
| EP4027990A1 (en) | 2022-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| TN2021000013A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| SE1651735A1 (en) | Substances for treatment of fatty liver-related conditions | |
| PH12020550844A1 (en) | Modified polypeptide with attenuated activity of citrate synthase and method for producing l-amino acid using the same | |
| MY169461A (en) | Pharmaceutical composition | |
| WO2011107653A3 (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
| EA200901365A1 (ru) | Стабилизированная фармацевтическая композиция, содержащая прегабалин | |
| ATE551328T1 (de) | Neuartige 5-substituierte hydantoine | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2024000804A (es) | Metodos para tratar la miocardiopatia hipertrofica. | |
| MX2021010208A (es) | Metodos que usan trigliceridos de cadena media administrados antes de una comida para reducir la glucosa postprandial generada por la comida. | |
| EP4400098A3 (en) | Co-amorphous forms of beta-lactoglobulin and a drug substance | |
| BR112018012410A2 (pt) | método e composição para o aumento da síntese de proteína e/ou força funcional musculares em mamíferos | |
| MX2022004515A (es) | Metodo y composicion para aumentar la sintesis de proteinas musculares. | |
| WO2017220041A3 (zh) | 苯扎贝特的药物组合物及其在类风湿性关节炎中的应用 | |
| MX2022004516A (es) | Metodo y composicion para aumentar la sintesis de proteinas musculares. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| WO2019008551A3 (en) | TRITERPENOID ENRICHED COATED COSTUS COMPOSITION AND PROCESS FOR PREPARING THE SAME | |
| MX2021015966A (es) | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. | |
| WO2007084839A3 (en) | Dietary methods and compositions for enhancing metabolism and reducting reactive oxygen species | |
| MX2012002154A (es) | Regulacion de la combinacion de aminoacidos utilizada para la sintesis de proteinas de fase aguda. | |
| EP4356961A3 (en) | Use of whey protein micelles for controlling postprandial glucose response | |
| WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof | |
| ZA202210779B (en) | Composition comprising trabectedin and an amino acid | |
| RU2010110718A (ru) | Способ профилактики и снижения деструкции цитоскелетных белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой |